Audio Categories: News

ThursdayOct 31, 2019 8:00 am

NetworkNewsAudio – Predictive Oncology (NASDAQ: POAI) Leveraging Vast Database of Drug-Response, Outcome Data

Related Editorial The field of precision medicine has latched upon what may well be the Holy Grail in the fight against cancer. When big data are utilized by teams of pathologists, data can be incredibly helpful, but when the right data are comprehensively analyzed by artificial intelligence (AI)-powered models, the data can be downright lifesaving. Predictive Oncology (NASDAQ: POAI) (POAI Profile) is in an enviable position in the precision-medicine industry due to its incredibly rich data set of more than 150,000 clinically validated cases on its molecular information platform, with 30,000-plus specific to ovarian cancer. The company is leveraging this…

Continue Reading

ThursdaySep 26, 2019 8:00 am

NetworkNewsAudio – Genprex Inc. (NASDAQ: GNPX) Building Encouraging New Breast Cancer Treatment Options

Related Editorial Advances in biotechnology look to deliver promising new treatment options against breast cancer. Independent researchers have found that Genprex Inc.’s (NASDAQ: GNPX) (GNPX Profile) TUSC2 prevented tumor growth against triple-negative breast cancer. Eli Lilly and Company (NYSE: LLY) is focusing on those patients with the greatest need and, in the process, has developed a new breast-cancer treatment option. Roche Holding (OTCQX: RHHBY) is expanding the use of its biotech to both identify and treat patients with challenging breast cancers. AbbVie Inc. (NYSE: ABBV) has been rapidly increasing its research, targeting more than 15 different types of cancer. AstraZeneca…

Continue Reading

FridaySep 06, 2019 8:00 am

NetworkNewsAudio – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Making Significant Advances in Drug Delivery

Related Editorial Drugs play an essential role in treating anything from a mild headache to life-threatening disease — and everything in between. While effectiveness of drugs is what most often captures the spotlight, that effectiveness is closely associated with the drug-delivery technology used, and innovation in this space may have a huge impact on how successful a drug can be. Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) (LXRP Profile) has developed one of the most innovative drug-delivery systems seen in years, a system that can be used to deliver a wide range of drugs in a more palatable and effective…

Continue Reading

FridayAug 23, 2019 8:00 am

NetworkNewsAudio – Genprex Inc. (NASDAQ: GNPX) Making Headway in Clinical Program Expansion, Company Growth

Related Editorial Biotech and biopharma industry leaders are posting record financials and hitting milestone markers in their research and growth, good indicators of a strong market with potential for robust returns on investment. Genprex Inc. (NASDAQ: GNPX) (GNPX Profile) has completed key steps in its overall strategy to expand its clinical development programs and bring Oncoprex(TM) immunogene therapy, its lead drug candidate, to commercialization. Over the past five years, Amgen Inc. (NASDAQ: AMGN) has invested nearly $19 billion in R&D and, as a result, is now advancing a record number of clinical assets. Biogen Inc. (NASDAQ: BIIB) has added four new programs to…

Continue Reading

FridayJun 14, 2019 8:00 am

NetworkNewsAudio – Pacific Rim Cobalt Corp. (CSE: BOLT) (OTCQB: PCRCF) (XFRA: NXFE) Employs Aggressive Exploration and Development Program Amid Surging Nickel Demand

Related Editorial Growth in demand for batteries is pushing up nickel production and economic change in Indonesia. Nickel is an essential component in batteries, including those for cars and phones. Demand for metals is growing, most importantly in China, a major battery manufacturer. Indonesia is the world’s largest nickel producer. The country is working to expand its manufacturing sector, attracting investment from multinational industry and mining giants. Pacific Rim Cobalt Corporation (OTCQB: PCRCF) (CSE: BOLT) (PCRCF Profile) is making the most of Indonesian nickel through an aggressive exploration and development program there. VALE S.A. (NYSE: VALE), the world’s leading nickel…

Continue Reading

FridayJun 07, 2019 8:00 am

NetworkNewsAudio – Siyata Mobile Inc. (TSX.V: SIM) (OTCQX: SYATF) Meeting the Vital Communication Needs of First Responders

Related Editorial Communication platforms are ubiquitous, yet first responders still have difficulty communicating in emergencies. To meet the vital communication needs of first responders, Siyata Mobile Inc. (TSX.V: SIM) (OTCQX: SYATF) (SYATF Profile) leveraged its strong commercial experience in mission-critical communications systems and launched its FirstNet Ready Uniden® UV350, the first-to-market, in-vehicle device of its kind. FirstNet is being built in a public-private partnership with AT&T Inc. (NYSE: T) and the First Responder Network Authority, an independent authority within the U.S. Department of Commerce. FirstNet is continuously expanding coverage, capacity and capability of the platform while first responders currently on…

Continue Reading

FridayMay 31, 2019 8:00 am

NetworkNewsAudio – Genprex Inc.’s (NASDAQ: GNPX) Proprietary Technology Platform Delivers Targeted Gene Therapeutics

Related Editorial Gene therapy is hot on the trail of killing cancer, and companies that deliver cures could see blockbuster returns. Pioneering a new paradigm in cancer therapeutics, Genprex Inc. (NASDAQ: GNPX) (GNPX Profile) is leveraging its patented technology platform to deliver powerful tumor-suppressing genes directly into cancer cells. Calithera Biosciences Inc. (NASDAQ: CALA) is looking for cures for cancer and other life-threatening diseases by discovering, developing and commercializing novel, small-molecule drugs that target tumor and immune cell metabolism. Adaptimmune Therapeutics plc (NASDAQ: ADAP) is developing novel cancer immunotherapy products for cancer patients by engineering T-cells to target and destroy cancer. Agenus Inc. (NASDAQ:…

Continue Reading

ThursdayMay 09, 2019 8:00 am

NetworkNewsAudio – Genprex Inc. (NASDAQ: GNPX) Developing Transformative Cancer Therapies

Related Editorial Gene therapies are gaining growing attention within the medical sector. Gene therapies help restore or replace the body’s damaged or missing genes. Groundbreaking treatments can stop the spread of cancer cells, cause cancer cells to die. Gene therapies are also being developed for ailments such as migraines, skin conditions and hemophilia. Genprex Inc. (NASDAQ: GNPX) (GNPX Profile) is developing gene therapies for the treatment of cancer, including its initial drug candidate, Oncoprex(TM) immunogene therapy. Spark Therapeutics Inc. (NASDAQ: ONCE) is tackling hereditary diseases through treatments that augment, suppress or replace mutated genes. Dyadic International Inc. (OTCQX: DYAI) uses…

Continue Reading

MondayApr 15, 2019 8:30 pm

NetworkNewsAudio – Redfund Capital Corp. (CSE: LOAN) (OTC: PNNRF) (Frankfurt: O3X4) Interview

About Redfund Capital Corp. Redfund intends to provide debt and equity funding in the middle to late stages of a target company’s development or in technologies that are developed and validated by revenues. The present focus of the merchant bank is on medical cannabis, hemp and CBD-related and healthcare-related companies. For more information, visit the company’s website at www.RedfundCapital.com. NOTE TO INVESTORS: The latest news and updates relating to PNNRF are available in the company’s newsroom at http://nnw.fm/PNNRF About NetworkNewsAudio NetworkNewsAudio, a service of NetworkNewsWire (NNW), allows you to sit back and listen to market updates, interviews and company press…

Continue Reading

FridayApr 12, 2019 8:00 am

NetworkNewsAudio – Genprex Inc. (NASDAQ: GNPX) Raising the Bar in Cancer Therapeutics

Related Editorial Several revolutionary gene therapies appear to be on the verge of delivering remarkable remedies for diseases that have previously been viewed as untreatable. Gene therapy is the next great leap forward in medicine, with several noteworthy programs underway looking to cure the incurable FDA expects 200 new gene and cell therapy INDs in next two years Genprex — and its initial product candidate Oncoprex — is pioneering a new approach to treating cancer. Built on decades of scientific research and innovation, gene therapy is the next frontier of medicine, determined to provide remedies for previously untreatable diseases and…

Continue Reading